Multiple System Atrophy: Clinical Trials

13 trials for Multiple System Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed. 13 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 13
Phase 21Completed 1

Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
UB-312 in Patients With Synucleinopathies
UB-312 Injection, Placebo Injection - Multiple System Atrophy, Parkinson Disease
Phase 1CompletedNYU Langone Health82023-05-312026-03-16
Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID
stellate ganglion block with 0.5% bupivacaine - Post Acute COVID-19 Syndrome, Long COVID
Phase 1CompletedJonathann Kuo, MD202023-01-032025-03-13
A Drug-Drug Interaction Study to Assess the CYP1A2 and CYP3A4 Interaction Potential of TEV-56286 (anle138b)
anle138b (TEV-56286), Fluvoxamine 100 mg QD for 5 days - Healthy Volunteers
Phase 1CompletedMODAG GmbH542022-09-122023-03-23
Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein
[18F]UCB-2897 - Parkinson Disease, Multisystem Atrophy
Phase 1CompletedInvicro52022-01-312025-02-20
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of anle138b in Parkinson's Disease
anle138b, Placebo - Parkinson Disease
Phase 1CompletedMODAG GmbH702020-12-222023-03-22
A First-in-Human Study of Single and Multiple Doses of anle138b in Healthy Subjects
anle138b, Placebo - Healthy Volunteers
Phase 1CompletedMODAG GmbH682019-12-062020-08-06
Safety and Tolerability of CS10BR05 Inj. in Subjects with Multiple System Atrophy
CS10BR05 - Multiple System Atrophy
Phase 1CompletedCorestemchemon, Inc.92018-04-132024-10-18
Automated Abdominal Binder for Orthostatic Hypotension
automated abdominal binder, Sham binder, Placebo - Orthostatic Hypotension, Autonomic Failure
Phase 1 / Phase 2CompletedVanderbilt University Medical Center282018-03-012026-05-05
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
Abdominal compression, Sham abdominal compression, Placebo pill - Orthostatic Hypotension, Pure Autonomic Failure
Phase 1CompletedVanderbilt University Medical Center212015-04-012026-05-05
Study Assessing Safety and Therapeutic Activity of AFFITOPE® PD01A and PD03A in Patients With Early MSA
AFFITOPE® PD01A + Adjuvant, AFFITOPE® PD03A + Adjuvant, Adjuvant without active component - Multiple System Atrophy, Neurodegenerative Diseases
Phase 1CompletedAffiris AG302014-12-112017-06-05
Efficacy of Therapeutic Interventions for Orthostatic Hypotension in Parkinson's Disease and Multiple System Atrophy
Fludrocortisone, Domperidone, Conservative Measures for Orthostatic Hypotension - Parkinson's Disease, Multiple System Atrophy
Phase 1CompletedRoyal Brisbane and Women's Hospital502005-01-012005-10-20
The Autonomic Nervous System and Obesity
Trimethaphan, Pseudoephedrine - OBESITY, HYPERTENSION
Phase 1CompletedVanderbilt University1282003-04-012018-03-01
Treatment of Supine Hypertension in Autonomic Failure
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox) - Hypertension
Phase 1CompletedVanderbilt University1522001-01-012017-10-13

Narrower conditions

Parkinson Disease (6)  ·  Neurodegenerative Diseases (4)  ·  Pure Autonomic Failure (4)  ·  Alzheimer Disease (3)  ·  Hypotension, Orthostatic (3)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (3)  ·  Shy-Drager Syndrome (3)  ·  Tauopathies (3)  ·  Hypertension (2)  ·  Autonomic Nervous System Diseases (1)  ·  COVID-19 (1)  ·  Dysautonomia like disorder (1)  ·  Obesity (1)  ·  Post-Acute COVID-19 Syndrome (1)

Broader conditions

Basal Ganglia Diseases (13)  ·  Brain Diseases (13)  ·  Central Nervous System Diseases (13)  ·  Movement Disorders (13)  ·  Nervous System Diseases (13)  ·  Primary Dysautonomias (13)  ·  Autonomic Nervous System Diseases (12)  ·  Synucleinopathies (11)  ·  Neurodegenerative Diseases (7)  ·  Cardiovascular Diseases (6)  ·  Hypotension (6)  ·  Parkinsonian Disorders (6)  ·  Vascular Diseases (6)  ·  Dementia (3)  ·  Mental Disorders (3)

Interventions

3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole (3)  ·  Midodrine (2)  ·  Adjuvants, Pharmaceutic (1)  ·  Arginine (1)  ·  Aspirin (1)  ·  Aspirin, Dipyridamole Drug Combination (1)  ·  Bosentan (1)  ·  Bupivacaine (1)  ·  Caffeine (1)  ·  Captopril (1)  ·  Carbidopa (1)  ·  Clonidine (1)  ·  Deamino Arginine Vasopressin (1)  ·  Diltiazem (1)  ·  Dipyridamole (1)

Sponsors

MODAG GmbH (3)  ·  Vanderbilt University (2)  ·  Vanderbilt University Medical Center (2)  ·  Affiris AG (1)  ·  Corestemchemon, Inc. (1)  ·  Invicro (1)  ·  Jonathann Kuo, MD (1)  ·  NYU Langone Health (1)  ·  Royal Brisbane and Women's Hospital (1)

Countries

United States (7)  ·  United Kingdom (3)  ·  Australia (1)  ·  France (1)  ·  South Korea (1)

Top investigators

Italo Biaggioni, MD (4)  ·  Luis E Okamoto, MD (2)  ·  Nand Singh, BSc, MD, DPM, MFPM (2)  ·  Amy Knorr, MD (1)  ·  David Russell, MD, Ph.D (1)  ·  Horacio Kaufmann, MD (1)  ·  Jonathan Evans, MD (1)  ·  Jonathann Kuo, MD (1)  ·  Joyce Gibbons, PA-C (1)  ·  Kerrie Schoffer, MBBS (1)  ·  Nand Singh, MD (1)  ·  Phil Hyu Lee, M.D. (1)  ·  Wassilios Meissner, MD, PhD (1)

Results publications

PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 17116758, PMID 18426998, PMID 19047577, PMID 19738158, PMID 22469621, PMID 22801444, PMID 23266540, PMID 32882100, PMID 34000076, PMID 35500536, PMID 9369256, PMID 9890307

NIH funding

R01HL144568 (2), 2014 (1), 2019 (1)